#### TRAINING UPDATE

Lab Location: Department: GEC, SGMC & WOMC Core Lab 
 Date Distributed:
 3/30/2021

 Due Date:
 4/30/2021

#### **DESCRIPTION OF PROCEDURE REVISION**

Name of procedure:

# D-Dimer SGMC.G04 v11

**Description of change(s):** 

Note: the QC changes have already been implemented (SOP revised to match practice)

Reason
Added QC freezing process, changed reconstituted exp to 16 hours
Changed frequency from 4 to 8 hours
Added QC validation
Removed reference to Satellite analyzer

This revised SOP will be implemented on April 6, 2021

Document your compliance with this training update by taking the quiz in the MTS system.

Technical	SOP
-----------	-----

Title	D-Dimer		
Prepared by	Ashkan Chini	Date:	4/7/2011
Owner	Robert SanLuis	Date:	6/3/2014

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
<i>Refer to the electronic signature page for approval and approval dates.</i>		

# **TABLE OF CONTENTS**

Test Information	2
Analytical Principle	2
Specimen Requirements	2
Reagents	3
Calibrators/Standards	4
Quality Control	5
Equipment And Supplies	7
Procedure	8
Calculations	9
Reporting Results And Repeat Criteria	.10
Expected Values	.11
Clinical Significance	.11
Procedure Notes	.11
Limitations Of Method	.12
Safety	.13
Related Documents	.13
References	.13
Revision History	.14
Addenda	.15
	Test Information Analytical Principle Specimen Requirements Reagents Calibrators/Standards Quality Control Equipment And Supplies Procedure Calculations Reporting Results And Repeat Criteria Expected Values Clinical Significance Procedure Notes Limitations Of Method Safety Related Documents References Revision History

# 1. TEST INFORMATION

Assay	<b>Method/Instrument</b>	Test Code
D - Dimer Quantitative	Immunoturbidometric STA <sup>®</sup> Compact <del>/ STA<sup>®</sup> Satellite</del>	DDIMER
Synonyms/Abbreviations D - Dimer		
Department		
Coagulation		

#### 2. ANALYTICAL PRINCIPLE

This assay is based on the change in turbidity of a microparticle suspension that is measured by photometry. A suspension of latex microparticles, coated by covalent bonding with monoclonal antibodies specific for D-dimer, is mixed with the test plasma whose D-dimer level is to be assayed. An antigen-antibody reaction takes place, leading to an agglutination of the latex microparticles which induces an increase in turbidity of the reaction medium. This increase in turbidity is reflected by an increase in absorbance, the latter being measured photometrically. The increase in absorbance is a function of the D-dimer level present in the test sample.

#### **3. SPECIMEN REQUIREMENTS**

#### **3.1** Patient Preparation

Component	Special Notations	
Fasting/Special Diets	N/A	
Specimen Collection and/or Timing	<ul> <li>Normal procedures for collecting plasma may be used for samples to be analyzed by this method.</li> <li>Vacutainer tube must be filled to the line to ensure the proper ratio of blood to anticoagulant.</li> </ul>	
Special Collection Procedures	If hematocrit >55%, refer to appendices A and B for collection instructions.	
Other	N/A	

#### 3.2 Specimen Type & Handling

	Criteria	
Туре	-Preferred	PLT Poor Plasma (sodium citrate)
	-Other Acceptable	None

Criteria		
Collection Container	Light blue top tube (3.2% sodium citrate)	
	Citrated blood 9:1 (blood to anticoagulant)	
Volume - Optimum	2.7 mL (9:1 blood to anticoagulant) in a 2.7 ml tube	
- Minimum	2.4 mL (9:1 blood to anticoagulant) in a 2.7 ml tube	
- Optimum	1.8 mL (9:1 blood to anticoagulant) in a 1.8 mL tube	
- Minimum	1.8 mL (9:1 blood to anticoagulant) in a 1.8 mL tube	
<b>Transport Container and</b>	Light blue vacutainer (as above) or a clean plastic screw	
Temperature	capped vial at room temperature.	
Stability & Storage	Room Temperature $(20 \pm 5^{\circ}C)$ : 8 hours	
Requirements	Refrigerated: Not recommended	
	Frozen plasma: 1 month at -20°C	
Specimen preparation	Centrifuge whole blood for specified time /speed	
	documented on each centrifuge for preparing platelet-poor	
	plasma.	
Unacceptable Specimens	Specimens that are unlabeled, improperly labeled, or those	
& Actions to Take	that do not meet the stated criteria are unacceptable.	
	Clotted or under-filled tubes are not accepted.	
	Request a recollection and credit the test with the	
	appropriate LIS English text code for "test not performed"	
	message.	
Compromising Physical	Moderate to gross hemolysis. Reject sample and request a	
Characteristics	recollection. Credit the test with appropriate LIS English	
	text code HMM (Specimen moderately hemolyzed) or	
	HMT (Specimen markedly hemolyzed)	
	Lipemia: Acceptable	
	Icterus: Acceptable	
Other Considerations	None	

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation.

#### 4. **REAGENTS**

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

#### 4.1 Reagent Summary

Reagents	Supplier & Catalog Number
STA - LIATEST <sup>®</sup> D – DI: Buffer & Latex	Diagnostic Stago (REF 00515)
STA – Owren-Koller Buffer	Diagnostic Stago (REF 00360)

Reagent 1 & 2	STA - LIATEST <sup>®</sup> D – DI: Buffer and Latex	
Container	Manufacturer supplied vial	
Storage	2-8°C	
Stability	Unopened reagents are stable until expiration date indicated on the box label.	
	With the STA-mini Reducer and perforated cap in place the stability of Reagents 1 and 2 after opening and in their original vials is 15 days on the Stago.	
Preparation	Allow Reagent 1 and 2 to stand at room temperature (18-25°C) for 15 minutes before use. Mix the reagents by gentle swirling of the vials without creating any bubbles. Then place the perforated cap on each vial.	
Reagent 3	STA – Owren-Koller Buffer	
Container	Manufacturer supplied vial	
Storage	2-8°C	
Stability	The buffer solution in intact bottles is stable until the expiration date indicated on the box label.	
	After opening it remains stable for 3 days on STA Compact and 6 days on STA Satellite.	
Preparation	Allow it to stand at room temperature (18-25°C) for 30 minutes before use.	

# 4.2 Reagent Preparations and Storage

#### 5. CALIBRATORS/STANDARDS

#### 5.1 Calibration Procedure

The pre-calibrated D-dimer values are identical for all the vials of each lot. To enter the calibration data on the analyzer, scan the barcode printed on the assay value insert across the instrument barcode reader.

The calibration data will be validated for the lot being used once the Stago D-dimer controls are run and tested.

The calibration curve is considered verified for the new reagent lot when both the STA<sup>®</sup>-LIATEST Control N + P are within acceptable range. The acceptable STA<sup>®</sup>-LIATEST Control N + P range is supplied by Stago. QC ranges must fall within the acceptable range which is established utilizing the peer group data in combination with our current/historic analytic performance.

To examine calibration curve on screen:

• Through the MAIN MENU under CALIB/CONTROL select CALIBRATION.

• Move the cursor to D-Dimer and press **Enter**. Curve will appear on analyzer screen.

To print calibration curve:

- While examining the curve on the analyzer screen, press ESC key for options.
- Select print Option Enter. Select Execute Enter.
- The curve will print along with the information on all reagents and control lot numbers. Also included are control results and ranges.

# 6. QUALITY CONTROL

#### 6.1 Controls Used

Controls	Supplier and Catalogue Number
STA - LIATEST Control N + P	Stago Diagnostic, Cat. No. 00526

#### 6.2 Control Preparations and Storage

Control	STA - LIATEST Control N + P	
Preparation	Reconstitute each vial of Reagent 1 or 2 with exactly 1 mL of Reagent Grade water. Allow the reconstituted material to stand at room temperature (18-25°C) for 30 minutes. Then, swirl the vial gently before use.	
	<ol> <li>Label the QC vial with date, time and initials - as well as expiration date. You may CHANGE THE EXPIRATION DATE TO 16 HOURS from the time you reconstituted it.</li> <li>Ensure the vial is well mixed. Pipette 1/2 the contents into a Microcup and use the barcode on the QC vial to load onto the instrument.</li> <li>The other half of the vial, re-cap and place into the freezer in the designated spot.</li> <li>After 8 hours, the QC will flag as expired. The next shift should then thaw the vials from the freezer, mix well and load.</li> </ol>	
Storage	2-8°C	
Stability	The reagents in intact vials are stable until the expiration date indicated on the box label, when stored at 2-8°C. Once reconstituted, Reagents 1 and 2 remain stable for 16 hours as demonstrated during validation.	

- 1. QC can be run automatically at pre-set intervals (in Test Set-up) or by ordering manually from the Quality Control Menu.
- 2. All control ranges are monitored automatically by the STA analyzer. If any controls are outside the  $\pm 2$  SD range, the instrument will audibly and visually alarm the operator. Otherwise, the results can be found in the individual QC files.

Control results are automatically filed in the STA QC file. All results for a 24hour period are converted to a "mean" value at midnight. This mean is used in the statistical data and is plotted on the Levy-Jennings chart as a daily mean.

3. To print all the QC data points for the D-Dimer test, perform the following procedure prior to midnight. From the MAIN MENU under CAL. /CONTROL select QUALITY CONTROL press Enter. Cursor to the D-Dimer test and press Enter to view the Levy-Jennings chart. Press F1 to view the results in tabular form. Press F6, select Execute then press Enter to print the individual values under current controls. Press ESC key to exit (back to graph). Press F2 or F3 to view other levels and continue with F1 to view the result list. On the STA Satellite, you may also print results by selecting DAILY CONTROLS from the Quality Control/Calibration tab and the selecting F6.

#### 6.3 Frequency

Controls are run every 8 hours of patient testing and with the change of any reagent used in test performance.

Controls are run after any maintenance is performed on the analyzer.

When not in use for patient testing, the STA Satellite QC is run every 24 hours.

Step	Action
1	The established QC ranges are in the QC file of the STA analyzers. The quality control results from the instrument are transmitted to Unity Real
	Time and can be viewed in that program. Any out-of-range QC results will be flagged.
2	If all controls are within QC parameters all sample results can be reported.
3	Rejected runs must be effectively addressed by corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be reanalyzed. Supervisor may override rejection of partial or complete runs only with detailed documentation that follows criteria that is approved by the Medical Director.
4	Corrective action documentation must include the following: QC rule(s) violated, the root cause of the problem, steps taken to correct the problem, how patient samples were handled, and the date and initials of the person recording the information. See the QC/QA SOP "QC Responsibilities" for more detail.
5	If the assay is down and results will not be reported in the scheduled turnaround time, clients will be notified of the situation.

## 6.4 Tolerance Limits and Criteria for Acceptable QC

#### 6.5 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

# 6.6 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples. Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Linearity must be verified with each new lot and at least every six months.
- Training must be successfully completed and documented prior to performing this test. This procedure must be incorporated into the departmental competency assessment program.
- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.
- Consult the Laboratory QC Program for complete details.

# 7. EQUIPMENT and SUPPLIES

# 7.1 Assay Platform

STA<sup>®</sup> Compact or STA Satellite Analyzers

# 7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range not to exceed -20 to -50°C.
- Centrifuge calibrated for preparing platelet-poor plasma

# 7.3 Supplies

- Cuvette Roll Diagnostic Stago
- STA brass micro reagent adapters Compact)
- STA brass micro sample adapters (Compact)
- Plastic micro cups
- STA Mini-Reducer
- Plastic transfer pipettes

• Glass micro cups

#### 8. **PROCEDURE**

**NOTE:** For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

8.1	Instrument Set-up Protocol
1	At the beginning of each shift, verify the instrument temperatures and availability of cuvettes and cleaner solution by accessing the system status screen from the main bar (For the back-up analyzer, STA Satellite, temperatures are verified daily when not in use for patient testing).
2	Document instrument temperatures as specified on maintenance log. If any temperatures are out of range, corrective action must be taken prior to patient samples being run.
3	Make sure there is an adequate supply of reagents in the analyzer and they are in date.
4	Load cuvettes and cleaner/wash solution on the analyzer.

8.2	Analytical Procedure
1	The STA system is designed to operate 24 hours a day. Refer to START-UP
	procedures in your analyzer reference manual as necessary.
2	Request quality control. Through MAIN MENU under CALIB. /CONTROL select
	QUALITY CONTROL and press Enter. Cursor to the FIB test.
	Select FIB by pressing F1 and then F10. Type in your Access Code to run the QC.
3	Load patient samples: Compact: Access the sample drawer(s) through the MAIN MENU, under LOADING, Select Sample, press <b>Enter</b> . After the drawer opens, identify the type of specimen, such as micro sample (press <b>F8</b> ), or stat (press <b>F12</b> ). Identify the sample by bar coding or manually entering on the keyboard the patient identification number and then placing the specimen into the drawer. <u>Satellite: Access loading (F1) and follow the prompts. If manually loading, select</u> <u>micro sample (F8) or stat (F12) as necessary.</u>
4	In MANUAL MODE, the operator must order the test(s) from the Selection menu or from the Recorded Profile/s Cursor to the test and press <b>Enter</b> to select. When all tests are ordered, press F10 to save.
5	In AUTO MODE, the Compact will automatically order the test(s) selected in the AUTO MODE profile.
6	If TELELOADING (Compact) or DOWNLOADING (Satellite) is selected as the AUTO MODE profile, the STA analyzer will query the host computer and download the test(s) as well as assign the status (i.e. stat).

8.2	Analytical Procedure
7	If there is not enough reagent(s) to run the test(s), the suspect reagent(s) will appear in red with the amount of depletion. This depletion of reagent will BLOCK the SAMPLE PIPETTING. When this occurs, add the necessary reagent(s) to run the samples by responding N (NO) to the warning message 'NEW TESTS ARE DELAYED - REACTIVATE?' Reagents can then be loaded in the drawer. By responding Y (YES) to the warning message 'NEW TESTS ARE DELAYED - REACTIVATE?', the instrument will continue to perform all tests for which there is sufficient reagent (i.e. while waiting for reagents to stabilize after reconstitution)
8	If a patient result falls outside the assay reportable range (4.0 $\mu$ g/mL), the instrument will automatically do a 1:5 dilution on the samples in question. This auto dilution will let the instrument report results up to 20.0 $\mu$ g/mL.
9	All patient results are displayed on the TEST PANEL screen and automatically print out and transmit if selected on the system status menu.
10	For results in question that need operator intervention, cursor to the identification number in the TEST PANEL screen and press enter. This will display the FILE PROCESSING screen. Follow the options on the left-hand side of the screen (i.e. <b>F3</b> - rerun test).

8.3	Reagent and QC Loading Instructions
1	When Reagent/QC material is reconstituted and ready for use proceed to step 2
2	From Home Page select Loading – Products (or select F2)
3	Compact: Scan the Reagent/QC
	Satellite: Place product in position so that analyzer reads product bar-code.
4	The Instrument will ask whether the volume is correct, or it needs to be modified.
5	Accept or modify the volume then press Enter
6	Load the Reagent/QC which was just scanned. Notes:
	Neoplastine CI Plus reagent vial requires to be sitting in the position which is systematically stirred by a lateral movement.
	For Satellite: Neoplastine CI Plus may be placed in any position of the correct size. Never place products that require stir bars next to each other.

# **NOTE:** In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

#### 9. CALCULATIONS

- 1. The STA automatically plots the results in delta OD off of a standard curve and converts the results to  $\mu$ g/ml FEU.
- The assay uses the sample undiluted. If the result is greater than the reportable range,
   4.0, a dependent test with a 1:5 dilution will be ordered to take the reportable range to
   20.0. The STA automatically corrects the result for the dilution change.

#### **10. REPORTING RESULTS AND REPEAT CRITERIA**

#### **10.1** Interpretation of Data

N/A

#### 10.2 Rounding

No rounding is necessary. The instrument reports results up to two decimal points.

#### **10.3** Units of Measure

µg/mL FEU

**Note:** The LIS uses an equivalent unit (mcg/mL FEU) to comply with HIS standard units.

#### 10.4 Clinically Reportable Range (CRR)

 $0.27-20.00\ \mu\text{g/mL}\ FEU$ 

#### **10.5** Review Patient Data

Each result is reviewed for error messages. Refer to the STA Compact or the STA Satellite Reference manual "Error messages" section for troubleshooting. Resolve any problems noted before issuing patient reports.

#### 10.6 Repeat Criteria and Resulting

The printout from the analyzer is reviewed for repeat criteria and samples are repeated if needed. Results will be transmitted to the LIS and released using the OEM function.

IF the result is	THEN		
< Mmin	Repeat, check for clots. If result is still <mmin, as<="" report="" td=""></mmin,>		
	<0.27 µg/mL FEU-REP		
> Mmax	Check for clots, repeat using the D-Di 1:5 test		
If D-Di 1:5 is quantifiable	Report the result with comment REP		
If D-Di 1:5 is > Mmax	Repeat. Report the result as $> 20.0 \ \mu g/mL FEU-REP$		
For any of the above situations, be sure the specimen is not under-filled or over-filled, then check the Hematocrit (HCT) result. If the HCT is greater than 55%, refer to appendices A and B for special tube preparation.			
Message Code			

Message	Code	
Verified by repeat analysis	Append –REP to the result.	

#### 11. EXPECTED VALUES

#### **11.1 Reference Ranges**

 $\leq 0.50 \; \mu g/mL \; FEU$ 

#### **11.2** Critical Values

None established

#### 11.3 Standard Required Messages

The following interpretative comment is automatically added to the report by the LIS:

"The D-Dimer test is used frequently to exclude an acute PE or DVT. In patients with a low to moderate clinical risk assessment and a D-Dimer result < 0.5 mcg/mL, the likelihood of a PE or DVT is very low. However, a thromboembolic event should not be excluded solely on the basis of the D-Dimer level. Increased levels of D-Dimer are associated with a PE, DVT, DIC, malignancies, inflammation, sepsis, surgery, trauma, pregnancy, and advancing patient age." [JAMA 2006 11:295(2): 199-207]

For patients greater than 49 years of age with a result >0.50, the following **additional** comment is also automatically added to the report by the LIS:

The application of age adjusted cut-off values for D-dimer increases specificity without modifying sensitivity, thereby improving the clinical utility of D-dimer testing in patients aged 50 or more.

Age (Y)	Age Adjusted Cut-off
<= 50	N/A
51-60	0.55 mcg/mL FEU (0.51-0.60)
61-70	0.65 mcg/mL FEU (0.61-0.70)
71-80	0.75 mcg/mL FEU (0.71-0.80)
> 80	0.80 mcg/mL FEU

Ref: Diagnostic Accuracy of Conventional or Age Adjusted D-Dimer cut-off values in Older Patients with suspected venous thromboembolism: Systematic Review and Meta-Analysis British Medical Journal 2013; 346:2492

# **12.** CLINICAL SIGNIFICANCE

D-Dimer quantitative assay detects the presence of Disseminated Intravascular Coagulation (DIC). In DIC, the fibrinolytic system is activated and therefore the D-Dimer level increases.

D-Dimer assays can help in the diagnosis of DIC in these cases. It is established that a normal D-Dimer level is an important factor to rule out the diagnosis of deep venous thromboses (DVT) or pulmonary embolisms (PE). The decrease of D-Dimer levels during heparin therapy for a DVT allows the monitoring of evolution and prognosis of the thrombosis. This decrease reflects the quality of the endogenic thrombolysis. The D-Dimer level increases during the activation states of coagulation because they induce the production of thrombin which is followed by the formation of fibrin and leads to fibrinolysis, the latter being most frequently reactive. The D-Dimer level thus increases following coagulation activation.

Increased levels of D-Dimer have been reported in post-operative period, cancers, cirrhosis, and hemorrhages.

#### **13. PROCEDURE NOTES**

- FDA Status: Approved/cleared
- Validated Test Modifications: None
- The detection threshold of the STA<sup>®</sup> Liatest<sup>®</sup> D-Dimer on the STA<sup>®</sup> Compact is 0.27 μg/mL FEU. The printout limits are pre-set at 0.27 – 4.00 μg/mL FEU. When a dependent test is set-up to extend the reportable range of the main test, the printout limit should be extended to 20.00 μg/mL FEU.
- 2. The STA<sup>®</sup> Liatest<sup>®</sup> D-Dimer results are expressed in FEU, Fibrinogen Equivalent Units. By definition, an FEU is the quantity of fibrinogen initially present that leads to the observed level of D-Dimer. In general, the actual quantity of D-Dimer is approximately half of an FEU.
- A >Mmax result on the primary assay dilution (1:1 dilution) indicates a result that is greater than 4.00 μg/mL FEU. In this case the analyzer will automatically do a 1:5 dilution to obtain the result.

# 14. LIMITATIONS OF METHOD

#### 14.1 Analytical Measurement Range (AMR)

 $0.27 - 4.00 \ \mu g/mL \ FEU$ 

#### 14.2 Precision

Different plasmas were used for the intra assay and inter assay reproducibility studies on the STA<sup>®</sup>-R.

	Repeat	tability	Within-laboratory Precision		
Sample	Sample 1 Sample 2		Sample 1	Sample 2	
Mean (µg/mL)	0.67	2.20	0.67	2.20	
SD ( $\mu g/mL$ )	0.042	0.049	0.049	0.085	

# 14.3 Interfering Substances

- 1. Cloudy plasmas may lead to an under-estimation of the D-Dimer level. Ensure that the absorbance value at 540 nm of the plasma diluted 1:6 with STA<sup>®</sup> Owren-Koller buffer is < 0.35.
- 2. Concentration of Fibrinogen Degradation Products greater than 15  $\mu$ g/ml may lead to an over-estimation of the D-Dimer level.
- 3. The presence of rheumatoid factor at a level greater than 50 IU/ml may lead to an over-estimation of the D-Dimer level.
- 4. The STA<sup>®</sup> Liatest<sup>®</sup> D-Dimer is insensitive to fibrinogen and the E fragment. A low cross-reactivity is observed with the D fragment.
- 5. The STA<sup>®</sup> Liatest<sup>®</sup> D-Dimer is insensitive to the following substances: hemoglobin (up to 2 g/l); conjugated bilirubin (up to 290 mg/L); unconjugated bilirubin (up to 200 mg/L); unfractionated heparin (up to 2 IU/mL; LMWH (up to 2 anti-Xa IU/ml)

# 14.4 Clinical Sensitivity/Specificity/Predictive Values

This test is appropriately sensitive for the exclusion of DVT and PE:

- negative predictive value (NPV), sensitivity and specificity of 100%, 100% and 55.2% for DVT exclusion, respectively
- NPV, sensitivity and specificity of 99.7%, 97.0% and 75.5% for PE exclusion, respectively

# **15. SAFETY**

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

# **16. RELATED DOCUMENTS**

- 1. Laboratory Quality Control Program
- 2. Laboratory Safety Manual
- 3. Safety Data Sheets (SDS)
- 4. Specimen Acceptability Requirements (Lab policy)
- 5. Repeat Testing Requirements (Lab policy)
- 6. STA Compact Operating Instructions, Coagulation procedure
- 7. STA Satellite Operating Instructions, Coagulation procedure
- 8. Verification of Platelet Poor Plasma, Coagulation procedure
- 9. Current package insert for STA<sup>®</sup> LIATEST D-DIMER

10. AHC System D-Dimer Quality Control Stability (VC.770)

# **17. REFERENCES**

- 1. van der Graaf F, et. al., Exclusion of Deep Venous Thrombosis with D-Dimer Testing, Thromb Haemost. 2000;83:191-198
- 2. Diagnostic Stago STA® LIATEST D-DIMER package insert: Revised Jan 2018

- STA LIATEST Control N + P (REF 00526): citrated control plasmas normal and abnormal levels; Control Plasmas for Assays of Coagulation Parameters on STA<sup>®</sup>, Revised 07/2017
- 4. STA<sup>®</sup> Compact Operators Manual. STA<sup>®</sup> DSI-TSD-SM August 2004, STA<sup>®</sup> DSI-TSD-US April 2003, and V1.3 revised February 2003.
- 5. STA Satellite reference Manual 0931275F 4/2016
- 6. Diagnostic Stago Owren-Koller Buffer Solution for Coagulation Tests, revised June 2018
- Diagnostic Accuracy of Conventional or Age Adjusted D-Dimer cut-off values in Older Patients with suspected venous thromboembolism: Systematic Review and Meta-Analysis British Medical Journal 2013; 346:2492
- 8. D-Dimer for the Exclusion of Thromboembolism (DiET) Study Completed, STAGO Website article, http://www.stago-us.com/news-events

Version	Date	Section	Reason	Reviser	Approval
			Supersedes G003.006		
000	6/11/12	2.0	Update to match package insert	J.Buss	J. Buss, RSL
000	6/11/12	3.2	Add frozen temperature	J.Buss	J. Buss, RSL
000	6/11/12	4.1	Remove Millipore water	J. Buss	J. Buss, RSL
000	6/11/12	4.2	D-DI reagent open stability edited	J.Buss	J. Buss, RSL
000	6/11/12	6.3	Add QC performed after maintenance	J.Buss	J. Buss, RSL
000	6/11/12	15	Update to standard wording	L. Barrett	J. Buss, RSL
001	6/3/14		Update owner	L Barrett	R SanLuis
001	6/3/14	3.1	Add reference to Appendices	A Chini	R SanLuis
001	6/3/14	3.2	Update tube volumes	A Chini	R SanLuis
001	6/3/14	4.2	Change storage temp and prep for buffer	A Chini	R SanLuis
001	6/3/14	6.2	Add step to print QC	A Chini	R SanLuis
001	6/3/14	10.4	Change CRR lower value	A Chini	R SanLuis
001	6/3/14	10.5	Add instruction for Hct >55	A Chini	R SanLuis
001	6/3/14	13, 14.1	Change lower value of analytical range	A Chini	R SanLuis
001	6/3/14	14.3	Update to match package insert	A Chini	R SanLuis
001	6/3/14	16	Update titles	L Barrett	R SanLuis
001	6/3/14	19	Add Appendix A and B	A Chini	R SanLuis
001	6/3/14	Footer	Version # leading zero's dropped due to new EDCS in use as of $10/7/13$ .	L Barrett	R SanLuis
2	4/7/15	6.4, 6.6	Replace LIS with Unity Real Time	L Barrett	R SanLuis
2	4/7/15	10.5	Correct <mmin reporting="" td="" value<=""><td>L Barrett</td><td>R SanLuis</td></mmin>	L Barrett	R SanLuis
3	1/12/16	3.2	Change whole blood to plasma	A Chini	R SanLuis
3	1/12/16	4	Delete reagent grade water	A Chini	R SanLuis

## **18. REVISION HISTORY**

Title: **D-Dimer** 

Version	Date	Section	Reason	Reviser	Approval
3	1/12/16	5	Add explanation for Liatest D-dimer and Bio-Rad QC. Add Liatest QC info.	A Chini	R SanLuis
3	1/12/16	6.1, 6.2	Update to Bio-Rad QC	A Chini	R SanLuis
3	1/12/16	6.2	Add instruction for loading onboard	A Chini	R SanLuis
3	1/12/16	6.5	Update to match auto verification system	A Chini	R SanLuis
3	1/12/16	6.7	Add TEa criteria, linearity check with log change, QC sent to Bio-Rad monthly	A Chini	R SanLuis
3	1/12/16	7.3	Add micro adapter and glass micro cups	A Chini	R SanLuis
3	1/12/16	14.2	Update precision data	A Chini	R SanLuis
3	1/12/16	17	Add Bio-Rad QC	A Chini	R SanLuis
4	7/25/16	Header	Add other sites	L Barrett	R SanLuis
4	7/25/16	5.1	Removed Bio-Rad QC information	A Chini	R SanLuis
4	7/25/16	6.1, 6.2	Replace Bio-Rad QC with STA Coag Controls	A Chini	R SanLuis
4	7/25/16	6.7	Remove QC submission to Bio-Rad	A Chini	R SanLuis
4	7/25/16	8.3	Add QC/Reagent Loading Instructions	A Chini	R SanLuis
4	7/25/16	11.3	Move report comment from 10.5	L Barrett	R SanLuis
4	7/25/16	17	Remove Bio-Rad insert	A Chini	R SanLuis
5	1/23/17	4, 6	Remove individual section labeling instructions and add general one	L Barrett	R SanLuis
5	1/23/17	10.5	Review data moved from section 6	L Barrett	R SanLuis
5	1/23/17	11.3	Specify interpretation comment is included if result >0.50, add second report comment for >49 years old	L Barrett	R SanLuis
5	1/23/17	15	Update to new standard wording	L Barrett	R SanLuis
5	1/23/17	17	Add reference for age adjusted value	L Barrett	R SanLuis
6	5/1/17	6.3	Remove run QC at beginning of shift	L Barrett	R SanLuis
7	6/16/17	14.4	Add values	L Barrett	R SanLuis
7	6/16/17	17	Add reference for clinical specificity	L Barrett	R SanLuis
8	4/19/18	7.2	Change freezer range to match practice	L Barrett	R SanLuis
8	4/19/18	11.3	Update interpretation comment	L Barrett	R SanLuis
9	3/20/20	Header	Change WAH to WOMC	L Barrett	R SanLuis
9	3/20/20	1	Added Satellite analyzer	D Collier	R SanLuis
9	3/20/20	4.2	Added Satellite stability requirements	D Collier	R SanLuis
9	3/20/20	6.2, 6.3, 7	Added Satellite info	D Collier	R SanLuis
9	3/20/20	8	Generalized some steps, added Satellite specifics where different from Compact	D Collier	R SanLuis

Adventist HealthCare Site: Shady Grove Medical Center, White Oak Medical Center, Germantown Emergency Center

Version	Date	Section	Reason	Reviser	Approval
9	3/20/20	10.3	Added note for UOM on LIS	L Barrett	R SanLuis
9	3/20/20	14.2	Corrected instrument to match insert	D Collier	R SanLuis
9	3/20/20	16	Added Satellite Operation SOP	D Collier	R SanLuis
9	3/20/20	17	Updated dates, added Satellite manual	D Collier	R SanLuis
10	3/24/21	6.2	Added QC freezing process, changed reconstituted exp to 16 hours	L Barrett	R SanLuis
10	3/24/21	6.3	Changed frequency from 4 to 8 hours	L Barrett	R SanLuis
10	3/24/21	16	Added QC validation	L Barrett	R SanLuis
10	3/24/21	All	Removed reference to Satellite analyzer	L Barrett	R SanLuis

#### **19. ADDENDA**

- A. Instructions for Preparing Collection Tube for Hematocrit >55%
- B. Phlebotomist Instructions for Blood Collection

# Appendix A

# Instructions for Preparing Collection Tube for Hematocrit >55%

Explanation:

Polycythemia is a disease state in which the proportion of blood volume that is occupied by red blood cells increases - basically when Hematocrit (HCT) is greater than 55%. It can cause prolonged coagulation results.

When a prolonged coagulation result is obtained, check the specimen for a clot first.

If the specimen is not clotted, be sure the specimen is not under-filled or over-filled, then check the HCT result.

If a HCT result of greater than 55% is obtained, immediately notify the doctor or attending nurse and ask for a redraw using a special tube prepared by the lab.

#### To prepare a special tube in the lab use the following instructions and formula:

The anticoagulant volume in the collection tube must be adjusted to obtain a 9:1 ratio of blood to Sodium Citrate. Under or over-filling of the specially prepared collection tube is not acceptable. The vacuum in the collection tube will be broken to adjust the volume of collection anticoagulant. Because of this special collection technique, the stability for these whole blood specimens is reduced to four (4) hours after collection.

Formula to calculate the anticoagulant volume is: Anticoagulant in mL = [(100 - HCT) / (595 - HCT)] x Volume of blood

Example 1: Specimen with a 70% HCT in a 2.7 mL tube:

Patient with HCT of 70%				
Using a 2.7 mL tube				
Anticoagulant in mL = $[(100 - 70) / (595 - 70)] \times 2.7 = 0.15$ mL or 150 uL				
Pipette a 2.7 mL tube in a way to leave only 150 uL of anticoagulant in there.				
A 2.7 mL tube contains 0.3mL anticoagulant; therefore remove 0.15mL				

Example 2: Specimen with a 70% HCT in a 1.8 mL tube:

Patient with HCT of 70%				
Using a 1.8 mL tube				
Anticoagulant in mL = $[(100 - 70) / (595 - 70)] \times 1.8 = 0.1 \text{ mL or } 100 \text{ uL}$				
Pipette a 1.8 mL tube in a way to leave only 100 uL of anticoagulant in there.				
A 1.8 mL tube contains 0.2mL anticoagulant; therefore remove 0.1mL				

Example 3: Specimen with a 60% HCT in a 2.7 mL tube:

Patient with HCT of 60%				
Using a 2.7 mL tube				
Anticoagulant in mL = $[(100 - 60) / (595 - 60)] \ge 2.7 = 0.2$ mL or 200 uL				
Pipette a 2.7 mL tube in a way to leave only 200 uL of anticoagulant in there.				
A 2.7 mL tube contains 0.3mL anticoagulant; therefore remove 0.1mL				

Example 4: Specimen with a 60% HCT in a 1.8 mL tube:

Patient with HCT of 60%				
Using a 1.8 mL tube				
Anticoagulant in mL = $[(100 - 60) / (595 - 60)] \times 1.8 = 0.13$ mL or 130 uL				
Pipette a 1.8 mL tube in a way to leave only 130 uL of anticoagulant in there.				
A 1.8 mL tube contains 0.2mL anticoagulant; therefore remove 0.07mL				

# Appendix B

# **Phlebotomist Instructions for Blood Collection**

The technologist will prepare a special tube in which the anticoagulant has been adjusted, therefore the tube is not vacuumed. The technologist will inform the phlebotomist of the exact amount of blood needed to fill the tube.

#### **Equipment and Supplies**

Latex free gloves Latex free tourniquet Latex free Band Aid or Tape Alcohol Prep (70% alcohol) 2x2 sterile gauze Collection tube Blood Collection Set 21 or 23 gauge winged set Blood Transfer Device 3mL syringe Biohazard bag Biohazard sharps container LIS collection list and label/Lab requisition

#### **Collection Steps**

- 1. Introduce yourself to the patient by stating your first and last name.
- 2. Positively identify the patient according to the SOP 'Patient Identification and Specimen Labeling', Phlebotomy procedure manual.
- 3. Wash hands. Apply gloves.
- 4. Explain the procedure to the patient and obtain patient's consent to draw blood.
- 5. Collect equipment and correct technologist-provided collection tube.
- 6. Assemble equipment and break needle and syringe seals in the presence of the patient.
- 7. Apply tourniquet about midway between the elbow and the shoulder 3-4 inches above the venipuncture site). Place patient's arm in a downward position to prevent reflux of 'backflow' of blood from the tube into the venous system. Ask the patient to close hand gently.
- 8. Palpate/feel for vein locating a vein that will flow fast (reducing the possibility of the blood clotting).
- 9. Clean the area for venipuncture with a 70% alcohol pad decontaminating the collection site.
- 10. Allow the area to air-dry completely.
- 11. Assemble the 21 or 23 gauge winged set to the 3mL syringe. Pull back the plunger to dispel all the air out of the syringe.
- 12. With the bevel up, align the needle with the vein while holding the skin taut. Insert the needle at a 15-30 degree angle with the skin. Remove your hand from drawing the skin taut. Grasp the syringe and draw back bringing the plunger tip to the exact amount of blood requested by the technologist.
- 13. Release the tourniquet. Ask the patient to open hand.

- 14. Place gauze above the puncture site and remove the needle while simultaneously applying pressure on the puncture sit. Firmly activate needle safety shield, a click must be heard to ensure that the safety shield is secure.
- 15. Remove 21 or 23 gauge winged set from syringe.
- 16. Attach the blood-filled syringe to the Blood Transfer Device.
- 17. Connect the Blood Transfer Device to the un-vacuumed tube, provided by the technologist, and slow and gently fill the collection tube. DO NOT FORCE blood into tube. Pressure can lead to tube explosion and blood exposure.
- 18. Place the cap on the tube and invert a few times to make sure the anticoagulant is mixed with blood.
- 19. Dispose of all blood collection equipment into the nearest sharps container. DO NOT disassemble the syringe from the Blood Transfer Device.
- 20. Dispose of all other used materials in appropriate container and wash hands.
- 21. Label the sample with the LIS collection label and write the time, date, and your tech code.
- 22. Transport specimen to the Lab.